Portfolio at a glance
Securities as at September 30, 2021
|
Company |
|
Number of securities |
|
Change since 31.12.2020 |
|
Local currency |
|
Share price |
|
Market value in CHF mn |
|
In % of securities |
|
In % of shareholders' equity |
|
In % of company |
|
Moderna |
|
1 678 349 |
|
(1 176 614) |
|
USD |
|
384.86 |
|
601.8 |
|
14.7% |
|
15.7% |
|
0.4% |
|
Ionis Pharmaceuticals |
|
9 112 973 |
|
892 973 |
|
USD |
|
33.54 |
|
284.8 |
|
7.0% |
|
7.4% |
|
6.5% |
|
Argenx SE |
|
955 538 |
|
34 206 |
|
USD |
|
302.00 |
|
268.9 |
|
6.6% |
|
7.0% |
|
1.9% |
|
Neurocrine Biosciences |
|
2 915 400 |
|
(119 600) |
|
USD |
|
95.91 |
|
260.5 |
|
6.4% |
|
6.8% |
|
3.1% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alnylam Pharmaceuticals |
|
1 110 000 |
|
(45 000) |
|
USD |
|
188.81 |
|
195.3 |
|
4.8% |
|
5.1% |
|
0.9% |
|
Incyte |
|
2 897 000 |
|
(3 000) |
|
USD |
|
68.78 |
|
185.6 |
|
4.5% |
|
4.8% |
|
1.3% |
|
Agios Pharmaceuticals |
|
4 304 992 |
|
146 090 |
|
USD |
|
46.15 |
|
185.1 |
|
4.5% |
|
4.8% |
|
7.3% |
|
Vertex Pharmaceuticals |
|
1 050 000 |
|
150 000 |
|
USD |
|
181.39 |
|
177.5 |
|
4.3% |
|
4.6% |
|
0.4% |
|
Fate Therapeutics |
|
3 186 336 |
|
1 156 336 |
|
USD |
|
59.27 |
|
176.0 |
|
4.3% |
|
4.6% |
|
3.3% |
|
Arvinas |
|
2 176 903 |
|
– |
|
USD |
|
82.18 |
|
166.7 |
|
4.1% |
|
4.3% |
|
4.1% |
|
Macrogenics |
|
7 075 564 |
|
2 260 000 |
|
USD |
|
20.94 |
|
138.0 |
|
3.4% |
|
3.6% |
|
11.6% |
|
Biogen |
|
500 000 |
|
(37 000) |
|
USD |
|
282.99 |
|
131.8 |
|
3.2% |
|
3.4% |
|
0.3% |
|
Sage Therapeutics |
|
3 170 104 |
|
1 630 000 |
|
USD |
|
44.31 |
|
130.9 |
|
3.2% |
|
3.4% |
|
5.4% |
|
Intra-Cellular Therapies |
|
3 663 419 |
|
125 000 |
|
USD |
|
37.28 |
|
127.2 |
|
3.1% |
|
3.3% |
|
4.5% |
|
Myovant Sciences |
|
5 722 039 |
|
965 000 |
|
USD |
|
22.44 |
|
119.6 |
|
2.9% |
|
3.1% |
|
6.2% |
|
Relay Therapeutics |
|
3 735 962 |
|
2 326 605 |
|
USD |
|
31.53 |
|
109.7 |
|
2.7% |
|
2.9% |
|
4.0% |
|
Crispr Therapeutics |
|
949 584 |
|
48 700 |
|
USD |
|
111.93 |
|
99.0 |
|
2.4% |
|
2.6% |
|
1.2% |
|
Radius Health |
|
7 705 714 |
|
250 000 |
|
USD |
|
12.41 |
|
89.1 |
|
2.2% |
|
2.3% |
|
16.3% |
|
Revolution Medicines |
|
3 410 105 |
|
3 410 105 |
|
USD |
|
27.51 |
|
87.4 |
|
2.1% |
|
2.3% |
|
4.6% |
|
Scholar Rock Holding |
|
2 275 125 |
|
19 474 |
|
USD |
|
33.02 |
|
70.0 |
|
1.7% |
|
1.8% |
|
6.6% |
|
Molecular Templates |
|
10 792 003 |
|
4 411 672 |
|
USD |
|
6.71 |
|
67.5 |
|
1.6% |
|
1.8% |
|
19.2% |
|
Generation Bio Co. |
|
2 453 180 |
|
120 000 |
|
USD |
|
25.07 |
|
57.3 |
|
1.4% |
|
1.5% |
|
4.3% |
|
Exelixis |
|
2 835 000 |
|
– |
|
USD |
|
21.14 |
|
55.8 |
|
1.4% |
|
1.5% |
|
0.9% |
|
Esperion Therapeutics |
|
4 477 964 |
|
530 000 |
|
USD |
|
12.05 |
|
50.3 |
|
1.2% |
|
1.3% |
|
15.8% |
|
Beam Therapeutics |
|
606 821 |
|
210 000 |
|
USD |
|
87.01 |
|
49.2 |
|
1.2% |
|
1.3% |
|
0.9% |
|
Nektar Therapeutics |
|
2 620 676 |
|
– |
|
USD |
|
17.96 |
|
43.9 |
|
1.1% |
|
1.1% |
|
1.4% |
|
Essa Pharma |
|
5 015 814 |
|
5 015 814 |
|
USD |
|
8.00 |
|
37.4 |
|
0.9% |
|
1.0% |
|
11.4% |
|
Kezar Life Sciences |
|
4 533 148 |
|
– |
|
USD |
|
8.64 |
|
36.5 |
|
0.9% |
|
1.0% |
|
9.4% |
|
Mersana Therapeutics |
|
4 135 000 |
|
2 250 000 |
|
USD |
|
9.43 |
|
36.3 |
|
0.9% |
|
0.9% |
|
5.8% |
|
Black Diamond Therapeutics |
|
3 440 000 |
|
2 050 000 |
|
USD |
|
8.46 |
|
27.1 |
|
0.7% |
|
0.7% |
|
9.5% |
|
Homology Medicines |
|
1 737 122 |
|
– |
|
USD |
|
7.87 |
|
12.7 |
|
0.3% |
|
0.3% |
|
3.0% |
|
Wave Life Sciences |
|
2 602 858 |
|
– |
|
USD |
|
4.90 |
|
11.9 |
|
0.3% |
|
0.3% |
|
5.1% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alder Biopharmaceuticals – Contingent Value Right |
|
2 766 008 |
|
– |
|
USD |
|
0.88 |
|
2.3 |
|
0.1% |
|
0.1% |
|
|
|
Total securities |
|
|
|
|
|
|
|
|
|
4 093.1 |
|
100.0% |
|
106.8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other assets |
|
|
|
|
|
|
|
|
|
1.9 |
|
|
|
0.0% |
|
|
|
Other liabilities |
|
|
|
|
|
|
|
|
|
(261.8) |
|
|
|
(6.8%) |
|
|
|
Net asset value |
|
|
|
|
|
|
|
|
|
3 833.2 |
|
|
|
100.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exchange rate as at 30.09.2021: USD/CHF: 0.9317